explore -WSS

explore

author：entertainment 2025-10-01 18:23:34 - browse：1

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Listen: Racing for gene therapy & a pioneering approval

focus

WSS

Does good food count as health care? Study aims to find out

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Cancer drug shortages' outsize impact on ovarian cancer patients

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Why medical students are struggling with mental health

leisure time

explore

focus

Apple is now the first public company to be valued at $3 trillion

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

DIEP, the 'gold standard' of breast reconstruction, is under threat

Baltimore teen accused of firing into crowd during block party mass shooting

What does generative AI mean for health care? We asked experts

Patient advocates sound warning on FDA proposal on salt intake

BioMarin wins approval for gene therapy to treat hemophilia A

Beware the threat of staffing cuts at the CDC

Cancer drug shortages should be causing more outrage

Trump cancels press conference intended to dispute Georgia election interference charges

explore

Beware the threat of staffing cuts at the CDC

Living with Hashimoto's and celiac disease, and med school, too

The boys, now 6, who are gene therapy’s ‘edge case’ problem

FDA approves first treatment for ultra

Evacuations in place as 3 wildfires burn in eastern Washington state

Patient advocates sound warning on FDA proposal on salt intake

leisure time

hotspot

focus

Wikipedia